评估与预处理和后处理临床因素有关的四期咽喉癌患者在辅助新辅助化疗的同时联合化疗放疗治疗中1、3和5年生存率。本回顾性队列研究包括2008年至2020年在我们的三级转诊中心治疗的128例四期咽喉癌患者。回顾性评估了预处理和后处理的临床指标，包括营养状况和炎症标志物。所有患者的5年总体生存率为36.72%。1年和3年的疾病特异性生存率（DSS）分别为80%和63%，而1年和3年的无病生存率（DFS）分别为49%和40%。多元分析显示，术前血红蛋白（Hb）＜12 g/dL（风险比[HR] 2.551，95%可信区间[CI] 1.366-4.762，p＝0.003）、术前系统免疫炎症（SII）≥1751（HR 2.173，95% CI 1.015-4.652，p＝0.046）和术后系统炎症反应指数（SIRI）≥261（HR 2.074，95% CI 1.045-4.115，p＝0.037）是恶化的DSS的独立指标。术前Hb＜12 g/dl（HR 1.692，95% CI 1.019-2.809，p＝0.032）、术前SII≥1751（HR 1.968，95% CI 1.061-3.650，p＝0.032）和术后SII≥1690（HR 1.922，95% CI 1.105-3.345，p＝0.021）是恶化的DFS的独立指标。使用术前Hb、术前SII和术后SIRI开发了一个预测DSS的评分卡。术前Hb、术前SII、术后SII和术后SIRI与四期咽喉癌患者的生存率有关。开发的评分卡有助于生存预测和治疗调整。© 2023年，作者与Springer-Verlag GmbH Germany公司独家许可，Springer Nature的一部分。

To evaluate the pre-treatment and post-treatment clinical factors associated with rate of survival at 1, 3, and 5 years in stage IV oropharyngeal cancer patients treated with concurrent chemoradiation with/without neoadjuvant chemotherapy.This retrospective cohort study involved 128 Stage IV oropharyngeal cancer patients that were treated at our tertiary referral center between 2008 and 2020. The pre-treatment and post-treatment clinical parameters including nutritional status and inflammatory markers were retrospectively reviewed.The 5-year overall survival rate for all patients was 36.72%. The disease-specific survival (DSS) at 1-year and 3-year were 80% and 63%, whereas the disease-free survival (DFS) at 1-year and 3-year were 49% and 40%, respectively. In multivariate analyses, pretreatment hemoglobin (Hb) < 12 g/dL (hazard ratio [HR] 2.551, 95% confidence interval [CI] 1.366-4.762, p = 0.003), pretreatment systemic immune inflammation (SII) ≥ 1751 (HR 2.173, 95% CI 1.015-4.652, p = 0.046), and posttreatment systemic inflammation response index (SIRI) ≥ 261 (HR 2.074, 95% CI 1.045-4.115, p = 0.037) were independent indicators for worsened DSS. Pretreatment Hb < 12 g/dl (HR 1.692, 95% CI 1.019-2.809, p = 0.032), pretreatment SII ≥ 1751 (HR 1.968, 95% CI 1.061-3.650, p = 0.032), and posttreatment SII ≥ 1690 (HR 1.922, 95% CI 1.105-3.345, p = 0.021) were independent indicators for worsened DFS. A nomogram was developed using pretreatment Hb, pretreatment SII, and posttreatment SIRI to forecast DSS.The pretreatment Hb, pretreatment SII, posttreatment SII, and posttreatment SIRI are associated with survival in patients with stage IV oropharyngeal cancers. The developed nomogram aids in survival prediction and treatment adjustment.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.